|
Suchita Pakkala, Suresh S, Rarnalingam. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non small cell lung cancer therapy [J]. Clinical Ltng Cancer, 2009.17.
|
|
Witz I P. Tumor-micrcenvironment interaction:dangerous liaisons [J]. Advances in Cancer Research, 2008.203.
|
|
Mcdornell Co, Hill A D, Mcramara D A. Tumor micrometases:The influence of angiohanesis [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000(2):105.
|
|
Swisher S G, Roth J A, Komaki R. A phase Ⅱ trial of adenoviral mediate p53 gene transfer in conjunction with radiation therapy in patients with localized non small cell lung cancer [J]. Proceedings of the American Society of Clinical Oncology, 2002.461.
|
|
Willett C G, Boucher Y, Tomaso E. Direct evidencethat the VEGF-specificantibody bevacizurrab has antivascular effect in human rectal cancer [J]. Nat Mel, 2004.145.
|
|
薛聃, 周彦斌. 非小细胞肺癌分子靶向药物的研究进展 [J]. 国际内科学杂志, 2008(7):419.
|
|
耿丽, 王瑞. 恩度联合培美曲塞方案二线治疗晚期非小细胞肺癌临床观察 [J]. 医药论坛杂志, 2011, (12):63.
|
|
Coussens LM, Fingleton B, Matrisian L M. Matrix metalloproteinase inhibitors and cancer:trials and tribulations [J]. SCIENCE, 2002, (5564):2387.
|
|
Bissett D, O' Byme K J, yon Pawel J. Phase Ⅲ study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer [J]. Journal of Clinical Oncology, 2005(4):842.
|
|
Leigh N B, Paz-Ares L, Douillard J Y. Radnom ized phase Ⅲ study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer National Cancer Institute of Canadar-Clinical trials Group Study BR.18 [J]. Journal of Clinical Oncology, 2005, (12):2831.
|
|
FRYDW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy:progression from reversible to irreversible inhibitors [J]. Pharrmacol ther, 1999.207.
|
|
王洋, 梁岳培. 抗VEGF和抗EGFR靶向治疗非小细胞肺癌的研究进展 [J]. 临床医学工程, 2011(2):312.
|
|
HirschFR, Varella-Garcia, BunnPAJr. Epidermal growth factor receptor in non-small-cell lung carcinomas:correlation between gene copy number and protein expression and impact on prognosis [J]. Journal of Clinical Oncology, 2003, (20):3798.
|
|
Janne P A, Engelman J A, Johnson B E. Epidermal growth factor receptor mutations in non-small-cell lung cancer:implications for treatment and tumor biology [J]. Journal of Clinical Oncology, 2005.3227.
|
|
卢宝安, 张新伟, 任秀宝. 吉非替尼在非小细胞肺癌治疗中的研究进展 [J]. 中国肿瘤临床与康复, 2010(1):78.
|
|
吴洪斌. 吉非替尼不良反应的临床表现及其处理 [J]. 药物不良反应杂志, 2006(1):28.
|
|
张婷, 许海柱, 卢俊彦. 吉非替尼在非小细胞肺癌治疗中耐药机制的研究 [J]. 中国肿瘤临床与康复, 2013(2):189.
|
|
YADEN Y, SLIW KOW SKIMX. Untangling the ErbB signalingnetwork [J]. Nature Reviews Molecular Cell Biology, 2001(2):127.
|
|
陈志伟, 虞永峰, 李子明. 吉非替尼和西妥昔单抗联合治疗非小细胞肺癌的体外实验研究 [J]. 中国癌症杂志, 2010(4):275.
|
|
Kelleher F C, McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene [J]. EUROPEAN JOURNAL OF CANCER, 2010, (13):2357.
|
|
Soda M, TakadaS, TakeuchiK. Amouse model for EML4-ALK-positive lung cancer [J]. Proceedings of the National Academy of Sciences(USA), 2008, (50):19893.
|
下载:
苏公网安备 32100302010246号